4D Molecular Therapeutics, Inc. $FDMT Shares Purchased by Armistice Capital LLC

Armistice Capital LLC boosted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 76.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,936,000 shares of the company’s stock after buying an additional 840,000 shares during the period. Armistice Capital LLC owned 3.39% of 4D Molecular Therapeutics worth $14,520,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wexford Capital LP acquired a new stake in 4D Molecular Therapeutics in the third quarter worth $41,000. Daiwa Securities Group Inc. increased its position in 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the period. Martingale Asset Management L P increased its position in 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares during the period. Gabelli Funds LLC acquired a new stake in 4D Molecular Therapeutics in the fourth quarter worth $90,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the first quarter worth $39,000. 99.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. Jefferies Financial Group reissued a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Chardan Capital reissued a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $9.42 on Thursday. 4D Molecular Therapeutics, Inc. has a 1 year low of $3.68 and a 1 year high of $12.34. The stock has a market cap of $492.48 million, a price-to-earnings ratio of -3.67 and a beta of 2.75. The business has a fifty day moving average of $9.44 and a 200-day moving average of $9.14.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.